How important is removal of the parametrium at surgery for carcinoma of the cervix?

被引:271
作者
Covens, A
Rosen, B
Murphy, J
Laframboise, S
DePetrillo, AD
Lickrish, G
Colgan, T
Chapman, W
Shaw, P
机构
[1] Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Univ Hlth Network, Dept Obstet & Gynecol,Div Gynecol Oncol, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Univ Hlth Network, Dept Pathol, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
关键词
D O I
10.1006/gyno.2001.6493
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The aims of this study were (1) to determine the incidence and factors predictive for pathologic parametrial involvement in clinical stage IA(1/2) and IB1 cervical cancer after radical surgery and (2) to identify a population at low risk for pathologic parametrial involvement. Methods. All patient information was collected prospectively and extracted from a cervical cancer radical surgery database. Selection criteria for surgery were generally based upon tumor size, with the cutoff for surgery between 3 and 4 cm. Parametrial involvement (PI) was defined as either positive parametrial lymph nodes (PMLN) or malignant cells in the parametrial tissue (PT) (including lymphovascular channels) by either contiguous or discontiguous spread. Statistical analysis included the chi(2) test, the Wilcoxon rank test, and the Mantel-Haentzel test. Results. Between July 1984 and January 2000, 842 patients underwent radical surgery for clinical stage IA(1/2) and IB1 cervical cancer at our center. Forty-nine patients (6%) had positive pelvic lymph nodes. Thirty-three patients (4%) had pathologic PI, 8 in the PMLN and 25 in the PT (none had both). PI was associated with older age (42 vs 40 years, P<0.04), larger tumor size (2.2 vs 1.8 cm, P<0.04), higher incidence of capillary-lymphatic space invasion (85% vs 45%, P=0.0004), tumor grades 2 and 3 (95% vs 65%, P=0.001), greater depth of invasion (18.0 vs 5.0 mm, P<0.001), and pelvic lymph node metastases (44% vs 5%, P<0.0001). The incidence of PI in patients with tumor size less than or equal to2 cm, negative pelvic lymph nodes, and depth of invasion less than or equal to10 mm was 0.6%. Conclusion. Pathologic parametrial involvement in clinical stage IA(1/2) and /IB1 cervical cancer is uncommon. Acknowledging that almost all patients with pelvic lymph node metastases and a high proportion of patients with tumor invasion >10 mm will receive adjuvant radiation regardless of the radicality of surgery, a population at low risk for pathologic parametrial involvement can be identified. These patients are worthy of consideration for studies of less radical surgery performed in conjunction with pelvic lymphadenectomy. (C) 2002 Elsevier Science.
引用
收藏
页码:145 / 149
页数:5
相关论文
共 29 条
[1]   RADICAL HYSTERECTOMY FOR INVASIVE CERVICAL-CANCER - A 25-YEAR PROSPECTIVE EXPERIENCE WITH THE MIAMI TECHNIQUE [J].
AVERETTE, HE ;
NGUYEN, HN ;
DONATO, DM ;
PENALVER, MA ;
SEVIN, BU ;
ESTAPE, R ;
LITTLE, WA .
CANCER, 1993, 71 (04) :1422-1437
[2]  
Benedetti-Panici P, 2000, CANCER, V88, P2267, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2267::AID-CNCR10>3.0.CO
[3]  
2-9
[4]   THE SIGNIFICANCE OF MICROSCOPIC INVOLVEMENT OF THE PARAMETRIUM AND OR PELVIC LYMPH-NODES IN CERVICAL-CANCER STAGE-IB AND STAGE-IIA [J].
BLEKER, OP ;
KETTING, BW ;
VANWAYJENEECEN, B ;
KLOOSTERMAN, GJ .
GYNECOLOGIC ONCOLOGY, 1983, 16 (01) :56-62
[5]  
Broders AC, 1926, ARCH PATHOL LAB MED, V2, P376
[6]   PROGNOSTIC FACTORS AND OPERATIVE TREATMENT OF STAGE-IB TO STAGE-IIB CERVICAL-CANCER [J].
BURGHARDT, E ;
PICKEL, H ;
HAAS, J ;
LAHOUSEN, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 156 (04) :988-996
[7]   DIFFERENCES IN THE MORBIDITY OF RADICAL HYSTERECTOMY BETWEEN GYNECOLOGICAL ONCOLOGISTS [J].
COVENS, A ;
ROSEN, B ;
GIBBONS, A ;
OSBORNE, R ;
MURPHY, J ;
DEPETRILLO, A ;
LICKRISH, G ;
SHAW, P ;
COLGAN, T .
GYNECOLOGIC ONCOLOGY, 1993, 51 (01) :39-45
[8]   Changes in the demographics and perioperative care of stage IA2/IB1 cervical cancer over the past 16 years [J].
Covens, A ;
Rosen, B ;
Murphy, J ;
Laframboise, S ;
DePetrillo, AD ;
Lickrish, G ;
Colgan, T ;
Chapman, W ;
Shaw, P .
GYNECOLOGIC ONCOLOGY, 2001, 81 (02) :133-137
[9]  
Covens A, 1999, CANCER, V86, P2273, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2273::AID-CNCR15>3.0.CO
[10]  
2-C